Conferencias

Eye Tracking and Gating System for Proton Therapy of Uveal Melanomas
Presenting Author/Institution: Dongho Shin, Proton Therapy Center, National Cancer Center, Korea Background Ocular melanoma is an uncommon malignancy, usually occurring in the uvea of the eye. For asymptomatic patients and small tumors (<10 mm in diameter and <2 mm in height), observation is often an acceptable treatment. For

Interferon Therapy Delays Disease Recurrence and Prolongs Survival in Patients with Resected Melanoma
Jean-Jacques Grob, MD, professor dermatology, University of Marseille, Hopital Sante-Marguerite (Marseille, France), presented a study of interferon alfa-2a as adjuvant therapy in patients with resected (surgically removed) early stage melanoma. Melanoma is a cancer which arises in the pigment cells of the skin, mucuous membranes, eyes and

Cancer Vaccine Triggers Immune System to Recognize Melanoma
Unlike vaccines that are used to prevent infectious disease, cancer vaccines attempt to stimulate the body's own immune system to recognize cancer cells as foreign and destroy them. These researchers examined tyrosinase, a normal protein present in melanin (which gives moles their color), and in melanoma cells. Patients were treated with

Melanoma Patients Could be Spared Radical Surgery by Sentinel Node Mapping
A technique called "sentinel node mapping" can accurately diagnose the minority of patients whose melanoma has spread, while saving the majority from radical lymph node dissection surgery, according to results of a five-year, multi-center study. In sentinel node mapping, injections of radioisotope makers and blue dye are used to pinpoint the

The 6th World Conference on Melanoma
Conference Dates: September 2 - 9, 2005 Conference Location: Vancouver Convention & Exhibition Centre Sponsoring Group: WHO Melanoma Programme Conference Web Page URL: www.worldmelanoma.com Topics Covered: melanoma: surgery, clinical diagnosis, pathology, epidemiology, basic research, dermoscopy, sentinel node biopsy, genetic, vaccine